Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

bladder carcinoma in situ - Clinical Profile, Treatments & Trials | Kisho | Kisho

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for bladder carcinoma in situ, including VALRUBICIN (VALSTAR, approved 1998). An additional 1 compound holds orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status
VALSTAR	VALRUBICIN	—	1998	Available

Orphan Drug Designations

The following drugs have received orphan drug designation from the FDA for bladder carcinoma in situ. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
Interferon alfa-2b (recombinant)	Interferon alfa-2b (recombinant)	Schering Corporation	1988	—	Withdrawn

Gene therapy approaches for bladder carcinoma in situ have been reported in the published literature.

Clinical Trials

1 trial found

Explore Trials

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

1 clinical trial registered. Interventions under study include drug therapy. Pipeline includes 1 PHASE3. Research is primarily industry-sponsored.

161 publications have been identified in PubMed for bladder carcinoma in situ. Research spans Clinical Trial Publication (20%), Basic Science / Preclinical (20%), and Diagnostic / Biomarker (18%).

Research Type	Count	% of Total
Clinical study results	33	20%
Laboratory research	32	20%
Testing and diagnosis research	29	18%
Research summaries	24	15%
Disease patterns and progression	22	14%
New treatment approaches	14	9%
Patient case studies	7	4%

Recent Publications

Soma T (2026). [PMID: 41635525](https://pubmed.ncbi.nlm.nih.gov/41635525/). *BMJ Oncol*. [Review / Meta-Analysis]
Li H (2026). [PMID: 41698628](https://pubmed.ncbi.nlm.nih.gov/41698628/). *Photodiagnosis Photodyn Ther*. [Epidemiology / Natural History]
Lee HW (2026). [PMID: 40369748](https://pubmed.ncbi.nlm.nih.gov/40369748/). *Cancer Res Treat*. [Epidemiology / Natural History]
Nair MS (2026). [PMID: 41447755](https://pubmed.ncbi.nlm.nih.gov/41447755/). *Clin Genitourin Cancer*. [Clinical Trial Publication]
Xu Y (2026). [PMID: 41355953](https://pubmed.ncbi.nlm.nih.gov/41355953/). *Theranostics*. [Gene Therapy / Novel Therapeutics]
Zhao M (2026). [PMID: 41097820](https://pubmed.ncbi.nlm.nih.gov/41097820/). *The American journal of surgical pathology*. [Review / Meta-Analysis]
Lee CH (2026). [PMID: 42023708](https://pubmed.ncbi.nlm.nih.gov/42023708/). *Cochrane Database Syst Rev*. [Review / Meta-Analysis]
Zeng WR (2026). [PMID: 41956744](https://pubmed.ncbi.nlm.nih.gov/41956744/). *Zhonghua Bing Li Xue Za Zhi*. [Clinical Trial Publication]
Daneshmand S (2026). [PMID: 41062389](https://pubmed.ncbi.nlm.nih.gov/41062389/). *European urology*. [Gene Therapy / Novel Therapeutics]
Jiang Z (2026). [PMID: 42107019](https://pubmed.ncbi.nlm.nih.gov/42107019/). *J Cancer Res Clin Oncol*. [Basic Science / Preclinical]

Kisho

bladder carcinoma in situ

Overview

Diagnosis

Treatment

Approved Therapies

Orphan Drug Designations

Clinical Trials

Research Landscape

Recent Publications

Medical References

Questions for Your Care Team

Questions for Your Care Team

Latest News & Developments

Diagnostic and therapeutic challenges in intradiverticular bladder carcinoma: A case report.

bladder carcinoma in situ

Overview

Diagnosis

Treatment

Approved Therapies

Orphan Drug Designations

Clinical Trials

Research Landscape

Recent Publications

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Latest News & Developments

Diagnostic and therapeutic challenges in intradiverticular bladder carcinoma: A case report.